Leading European oncology center Gustave Roussy adopts OncoDNA’s OncoDEEP® Kit and automates library preparation and Target Enrichment using Bravo instrument.

Leading French and European comprehensive cancer center selects the OncoDEEP® Kit as the most complete solution with the highest number of relevant oncology biomarkers for use in its molecular laboratory.

Gosselies, Belgium and Paris, France, February 29, 2024 – OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases, today announced that it will be entering into a collaboration with Gustave Roussy, Europe’s leading oncology center, for the use of the recently-launched OncoDEEP® Kit. Gustave Roussy has chosen the OncoDEEP® kit as the best and most complete solution to be used for their clinical trial testing, as well as to be used in their translational research setting.

The OncoDEEP® Kit provides a comprehensive end-to-end solution for the rapid analysis and reporting of tumor molecular profiles. The OncoDEEP® Kit comes with a pre-defined suite of reagents for the sequencing of over 600 cancer genes and other relevant biomarkers in combination with OncoDNA’s curated data analysis. Gustave Roussy has evaluated the OncoDEEP® Kit as the assay with the most relevant target coverage, the easiest to implement in the lab, and the best technical performance. With the combination of an easy lab workflow and the included bioinformatics tools, the OncoDEEP® Kit is a user-friendly, comprehensive, and cost effective solution.

The kit incorporates Twist Bioscience’s enrichment and library preparation solutions. Also suited for automation, Twist Bioscience’s wetlab process has been optimized for the reliable analysis of somatic variants and translocations. The panel allows for the detection of variants as well as complex genomic signatures.

The OncoDEEP® assay comes with the OncoKDM tool which allows the user to explore the detailed QC and performance parameters of each analyzed sample. The use of OncoKDM provides access to a proprietary biomarker database which is reviewed and revised daily, and currently includes more than 4,500,000 genetic variants, 1,150 cancer drugs, and 7,000 clinical trials. The user-friendly cloud-based software tools make it easy for the user to generate clinically relevant patient reports.

Dr. Ludovic Lacroix, Molecular Pathology Research Lab (BMO) in AMMICa platform at Gustave Roussy commented:

“We are eager to start using the OncoDEEP® Kit for our translational research projects. The complete package of genome profiling and OncoKDM software, combined with the easy wet lab workflow and automation capabilities, will make this a cost-effective solution for good molecular characterisation of our research tumor cohorts.”

Jean-Pol Detiffe, Chief Strategy and Innovation Officer at OncoDNA stated:

“We are honored that the renowned BMO lab from Gustave Roussy Institute has chosen to use our OncoDEEP® Kit for biomarker testing by it research platform. We are looking forward to feedback from this collaboration that will help us further fine-tune our kit, so that we can continue to offer a comprehensive and competitive kit to more hospitals in the future.”

About OncoDNA

OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late stage cancer patients, but also supports research and drug development in cancer and genetic diseases. Since the early days in 2012, OncoDNA has grown into a corporate group of companies with world-renowned expertise. The Group offers a unique portfolio that combines NGS services, biomarker testing, data analysis software and clinical decision support tools. OncoDNA is headquartered in Belgium, and its entities – BioSequence and IntegraGen – are based in Spain and France, respectively. The Group employs over 100 people across 9 countries, works with an international network of 35 distributors, and collaborates with both European-based and US-based subcontracted and accredited laboratories.


About Gustave Roussy

Ranked as the leading French and European Cancer Centre and fourth in the world, Gustave Roussy is a centre with comprehensive expertise and is devoted entirely to patients suffering with cancer. The Institute is a founding member of the Paris Saclay Cancer Cluster. It is a source of diagnostic and therapeutic advances. It caters for almost 50,000 patients per year and its approach is one that integrates research, patient care and teaching. It is specialized in the treatment of rare cancers and complex tumors and it treats all cancers in patients of any age. Its care is personalized and combines the most advanced medical methods with an appreciation of the patient’s human requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient’s life are respected. 4,100 professionals work on its two campuses: Villejuif and Chevilly-Larue. Gustave Roussy brings together the skills, which are essential for the highest quality research in oncology: 40% of patients treated are included in clinical studies.

For further information: www.gustaveroussy.fr/en, Twitter, Facebook, LinkedIn, Instagram

Media contact:

Koenraad Eycken
Chief Product Officer, OncoDNA

You may also be interested in these resources

Share This